[1] |
HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Online ahead of print]
|
[2] |
SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802.
|
[3] |
GHANY MG, WAHED A, FELD JJ, et al. Indeterminant phenotypes of HBeAg-negtive chronic hepatitis B and predictors of transition to inactive or active disease: Outcomes of a prospective North Anerican Cohort[C]. AASLD 2020: Abstract (poster 764).
|
[4] |
YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
|
[5] |
BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613.
|
[6] |
TESTONI B, LEBOSSÉ F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625. DOI: 10.1016/j.jhep.2018.11.030.
|
[7] |
CHEN EQ, WANG ML, TAO YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat, 2019, 26(5): 586-595. DOI: 10.1111/jvh.13061.
|
[8] |
LOGGI E, VUKOTIC R, CONTI F, et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(5): 568-575. DOI: 10.1111/jvh.13054.
|
[9] |
BRUNETTO MR, CAREY I, MAASOUMY B, et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis[J]. Aliment Pharmacol Ther, 2021, 53(6): 733-744. DOI: 10.1111/apt.16258.
|
[10] |
DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.
|